For decades, the "amyloid hypothesis" has dominated neurobiology, yet drugs targeting plaque clearance have yielded mixed clinical success [1] [2]. A paradigm shift is now underway, focusing on geroscience: the idea that targeting biological aging itself is the most effective way to prevent Alzheimer’s disease (AD) [3]. At the center of this movement is rapamycin…

Researchers now pursue human longevity through synergistic protocols instead of single-drug solutions. These combinations target the complex network of aging hallmarks simultaneously. Rapamycin remains the most effective drug for extending mammalian lifespans. However, real-world users often "stack" it with other interventions. People combine it with metformin, NAD+ precursors, and lifestyle changes. These additions enhance both…

The transition of rapamycin (sirolimus) from a soil-dwelling byproduct of Easter Island to the center of the longevity drug ethical debate represents a paradigm shift in preventive medicine. While this macrolide remains the only pharmacological intervention proven to extend lifespan across nearly all model organisms, its increasing off-label adoption by healthy "biohackers" has ignited a…

Can a drug originally used in organ transplant medicine hold the key to preventing Alzheimer’s disease? As we move into 2025, Rapamycin has transitioned from a niche "longevity molecule" to a primary subject of intense clinical investigation for dementia. Rapamycin is an FDA-approved mTOR inhibitor that researchers believe may slow the biological processes of aging…